The New World Of Pharma – Markets, Messaging And The Flash Mob
Our look back at 2016 and at prospects for the year ahead plots a rush of often conflicting head and tail winds, all requiring unrelenting focus from the C-suite on what matters to preserving pharma's vital public license to operate. Events in the sales-leading US market remain the key driver of change and a test ground for managing the competitive and reputational challenges industry faces from a more restive – and powerful – customer base.
You may also be interested in...
Drug Pricing ‘Opacity,’ Degrees Of Transparency Debated By National Academies Panel
Second meeting of National Academies drug pricing committee was far-reaching discussion of several major themes, including PBM transparency, the political future for co-pay coupons and the next possible inflection point: the potential $1 million price tag for gene therapies.
Brexit: What Can The Life Sciences Industry Do About It?
With the UK seemingly heading towards an exit from the European Union in just two and a half years’ time, restrictions on the free movement of people, products and finance will impact the life science sector as much as, if not more than, many others.
Trump Win Is False Security For Drug Makers, Allergan CEO Warns
Industry should act on drug pricing now while there is a post-election reprieve, Allergan CEO Brent Saunders said during the Forbes Healthcare Summit. Trump is a populist who will jump on the next big pricing scandal, he said.